Traws Pharma (TRAW) Shares Outstanding (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Shares Outstanding (Entity) of $10.2 million for Q1 2026, up 45.89% year-over-year from $7.0 million in Q1 2025, and up 12.07% quarter-over-quarter from $9.1 million in Q4 2025.
Traws Pharma (TRAW) Shares Outstanding (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Shares Outstanding (Entity) for 15 consecutive years, with $10.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 45.89% year-over-year to $10.2 million; the TTM figure through Mar 2026 stood at $10.2 million (up 45.89% YoY), while the FY2025 annual figure was $9.1 million, up 484.01% from the prior year.
- Shares Outstanding (Entity) climbed to $10.2 million in Q1 2026 per TRAW's latest filing, from $9.1 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $10.2 million in Q1 2026 and bottomed at $835823.0 in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $3.0 million across 5 years, with a median of $843553.0 in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) rose 0.35% — and 2025, when it soared 725.78%.
- Traws Pharma's Shares Outstanding (Entity) stood at $837040.0 in 2022, then climbed by 0.38% to $840251.0 in 2023, then jumped by 84.79% to $1.6 million in 2024, then surged by 484.01% to $9.1 million in 2025, then rose by 12.07% to $10.2 million in 2026.
- Business Quant data shows TRAW's Shares Outstanding (Entity) at $10.2 million in Q1 2026, $9.1 million in Q4 2025, and $7.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Traws Pharma | 5.66 Mn | 639,491.99 | - | 10.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.64 Mn |
| Dec 31, 2025 | 8.23 Mn |
| Sep 30, 2025 | 8.82 Mn |
| Jun 30, 2025 | 5.82 Mn |
| Mar 31, 2025 | 6.97 Mn |
| Dec 31, 2024 | 1.55 Mn |
| Sep 30, 2024 | 961,530.00 |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 841,738.00 |
| Dec 31, 2023 | 839,555.00 |
| Sep 30, 2023 | 840,117.00 |
| Jun 30, 2023 | 839,191.00 |
| Mar 31, 2023 | 838,407.00 |
| Dec 31, 2022 | 836,329.00 |
| Sep 30, 2022 | 836,616.00 |
| Jun 30, 2022 | 836,163.00 |
| Mar 31, 2022 | 836,163.00 |
| Dec 31, 2021 | 673,288.00 |
| Sep 30, 2021 | 639,167.00 |
| Jun 30, 2021 | 631,235.00 |